CP
DAWN

CenterBook Partners’s Day One Biopharmaceuticals DAWN Stock Holding History

CenterBook Partners’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-11,836
Closed -$93.9K – 533
2025
Q1 		$93.9K Sell
11,836
-88,899
-88% -$958K 0.01% 466
2024
Q4 		$1.28M Buy
+100,735
New +$1.4M 0.08% 294

Other funds holding DAWN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CenterBook Partners's DAWN Position: Q2 2025 in Review

CenterBook Partners sold out of Day One Biopharmaceuticals (DAWN) in Q2 2025, closing a stake of 11,836 shares — an estimated $93.9K sold.

CenterBook Partners first reported a position in DAWN in Q4 2024 and held it in 2 quarters. The position peaked at $1.28M in Q4 2024. 174 funds tracked by Wall St. Rank hold DAWN as of Q2 2025.

  • CenterBook Partners reported no remaining Day One Biopharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • CenterBook Partners sold 11,836 Day One Biopharmaceuticals shares in Q2 2025, an estimated $93.9K.
  • CenterBook Partners first reported a position in Day One Biopharmaceuticals in Q4 2024 and held it in 2 quarters.
  • CenterBook Partners's Day One Biopharmaceuticals position peaked at $1.28M in Q4 2024.
  • 174 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2025.

Based on CenterBook Partners's 13F filing for Q2 2025, filed 12 Aug 2025.